Korro Bio, Inc. (KRRO) — 8-K Filings

8-K Filings (17)

• 8-K Filing — May 7, 2026
• 8-K Filing — Dec 18, 2025
• Korro Bio Announces Board and Executive Changes — Oct 8, 2025 Risk: medium
  Korro Bio, Inc. announced on October 7, 2025, changes in its board and executive compensation. The company, formerly known as Frequency Therapeutics, Inc., file
• Korro Bio Files 8-K on Shareholder Vote Matters — Jun 11, 2025 Risk: low
  Korro Bio, Inc. filed an 8-K on June 11, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain details about the s
• Korro Bio, Inc. Files 8-K: Leadership and Compensation Changes — Mar 27, 2025 Risk: medium
  On March 27, 2025, Korro Bio, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates a shift in l
• Korro Bio Appoints New Director, Officer Compensation Details — Feb 11, 2025 Risk: medium
  Korro Bio, Inc. announced on February 11, 2025, the departure of Director Dr. Peter S. Kim and the election of Dr. David L. Donabedian as a new director. The co
• Korro Bio Files 8-K — Jan 13, 2025 Risk: low
  Korro Bio, Inc. filed an 8-K on January 13, 2025, reporting other events and financial statements. The company, formerly known as Frequency Therapeutics, Inc. u
• Korro Bio Files 8-K — Nov 21, 2024 Risk: low
  Korro Bio, Inc. filed an 8-K on November 21, 2024, to report other events and financial statements. The company, formerly known as Frequency Therapeutics, Inc.
• Korro Bio Files 8-K — Nov 4, 2024 Risk: low
  Korro Bio, Inc. filed an 8-K on November 4, 2024, to report other events and financial statements. The company, formerly known as Frequency Therapeutics, Inc. u
• Korro Bio Enters Material Definitive Agreement — Sep 16, 2024 Risk: medium
  Korro Bio, Inc. announced on September 13, 2024, that it entered into a material definitive agreement. The company, formerly known as Frequency Therapeutics, In
• Korro Bio Appoints New CMO & CSO, Sees CMO Depart — Aug 28, 2024 Risk: medium
  Korro Bio, Inc. announced on August 26, 2024, the appointment of Dr. Jessica Lee as Chief Medical Officer and Dr. David Chang as Chief Scientific Officer. The c
• Korro Bio Appoints New CMO, Elects Director — Jun 21, 2024 Risk: medium
  Korro Bio, Inc. announced on June 17, 2024, the appointment of Dr. Michael J. Yauch as Chief Medical Officer and the election of Dr. Sarah E. Kelley to its Boar
• Korro Bio, Inc. Files 8-K — Jun 12, 2024 Risk: low
  Korro Bio, Inc. filed an 8-K on June 11, 2024, reporting a change in its corporate structure. The company, formerly known as Frequency Therapeutics, Inc. until
• Novartis to Acquire Korro Bio for Up to $855M — Apr 22, 2024 Risk: medium
  Korro Bio, Inc. announced on April 22, 2024, that it has entered into a definitive agreement to be acquired by Novartis AG. The transaction is valued at up to $
• Korro Bio, Inc. Files 8-K: Material Agreement & Equity Sales — Apr 18, 2024 Risk: medium
  Korro Bio, Inc. announced on April 17, 2024, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equity secur
• Korro Bio Files 8-K on Operations and Financials — Mar 26, 2024 Risk: low
  Korro Bio, Inc. filed an 8-K on March 26, 2024, reporting on its results of operations and financial condition. The filing also includes financial statements an
• Korro Bio Files 8-K for Routine Administrative Update — Jan 9, 2024
  Korro Bio, Inc. filed an 8-K on January 9, 2024, to report an "Other Event" and provide "Financial Statements and Exhibits." This filing primarily serves to upd

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX